Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 13/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.43 |
| ▸ | POLG | P54098 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | POLD1 | P28340 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17971852 | 1.00 | P2RY2 (0.43) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL16575905 | 1.00 | P2RY2 (0.43) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL16575914 | 0.92 | P2RY2 (0.47) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL16575911 | 0.92 | POLA1 (0.44) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL17971866 | 0.92 | POLA1 (0.44) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL17971839 | 0.92 | P2RY2 (0.47) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL16575902 | 0.84 | P2RY2 (0.52) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL17971892 | 0.84 | P2RY2 (0.52) | P2RY2P2RY4POLA1P2RY6P2RY14 | |
| SCHEMBL21418544 | 0.83 | P2RY2 (0.35) | P2RY2P2RY4POLGPOLA1POLB | |
| SCHEMBL17971838 | 0.83 | P2RY2 (0.63) | P2RY2P2RY4POLA1P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | DEFENSE THREAT REDUCTION AGENCY, US DOD | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220595-A1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, NTPCR, TYMP | P2RY2 452/4885P2RY4 288/4885POLG 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.